For the quarter ended September 2026, Cencora (COR Quick QuoteCOR - Free Report) reported revenue of $88.35 billion, up 5.5% over the same period last year. EPS came in at $4.66, compared to $3.84 in the year-ago quarter.

The reported revenue represents a surprise of +0.22% over the Zacks Consensus Estimate of $88.16 billion. With the consensus EPS estimate being $4.56, the EPS surprise was +2.19%.

While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

Here is how Cencora performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

• Revenue- Total U.S. Healthcare Solutions: $78.29 billion versus the two-analyst average estimate of $78.26 billion. The reported number represents a year-over-year change of +3.3%.
• Revenue- Other: $2.3 billion versus $2.22 billion estimated by two analysts on average.
• Revenue- Intersegment eliminations: $-36.81 million compared to the $-39.71 million average estimate based on two analysts. The reported number represents a change of +645.8% year over year.
• Revenue- Total International Healthcare Solutions: $7.8 billion compared to the $7.75 billion average estimate based on two analysts. The reported number represents a change of -1.9% year over year.

View all Key Company Metrics for Cencora here>>>

Shares of Cencora have returned +7.6% over the past month versus the Zacks S&P 500 composite's -2% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term.